At the moment, the debt-to-equity of OHR Pharmaceutical, Inc. (NASDAQ:OHRP) is low, standing at 0.67, a figure that is less than the 29.86 average recorded by the industry. This means that the company is currently holding a debt level at 73,217. OHRP shares have a strong debt-to-equity ratio but their quick ratio which reads 5.50 is strong and might cause problems for them later in the future.

For the most recent quarter, the net income has dropped by -21.19%. This weakness in their income has affected them and thus decreased their earnings to -$775,410. The sustained growth in their revenue has helped boost their earnings per share.

They have recorded a -1066.13% declining earnings per share earnings.

The 12-month return on equity has significantly fallen to -78.45 in comparison to the same data for other companies in the same industry. This shows that there is a major weakness within the organization over the past one year. Comparing them to other companies in the industry and the overall Healthcare sector, the industry average is 10.21 while 13.87 is of the sector.

The company’s ROA is -66.93 when compared to 7.87 for the stocks operating in the same industry. This can be attributed to the strength recorded in the net income produced by total assets. Comparing it to other companies in the sector, OHR Pharmaceutical, Inc. ROE is above 13.87 that of both the sector average.

Added to that, this ratio has surpassed the industry net margin that stands at -257.44.

Still some above discussed indicators of the $8.12M company show strength while others show weakness. There is little evidence at the moment to justify the expectation of the OHRP shares to either perform positively or negatively when compared to other stocks. The primary strengths of OHR Pharmaceutical, Inc. can be witnessed in its increased revenue, growing earnings per share, higher return on equity, increased operating cash and high net margin. Subsequently, financial analysis have also identified some weak areas that includes high debt, relatively high P/E ratio, lower return on assets and low net margin.